Business
New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021
- LIVMARLI (maralixibat) late-breaker oral presentation on a six-year event-free survival analysis in Alagille syndrome compared to a natural history cohort;
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n- LIVMARLI (maralixibat) late-breaker oral presentation on a six-year event-free survival analysis in Alagille syndrome compared to a natural history cohort; selected for Best of the Liver Meeting\n\n- Second late-breaker presentation to highlight predictors of event-free survival in patients treated with maralixibat.\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that new data will be presented at the American Association for the Study of Liver Disease annual congress, The Liver Meeting®, November 12-15, 2021.\n\nHighlights of the meeting will take place during two late-breaker sessions where new analyses from LIVMARLI™ (maralixibat) oral solution clinical studies will be presented. The late-breaker oral presentation will provide real world evidence analytics on a six-year event-free survival analysis in patients with Alagille syndrome (ALGS) treated with maralixibat compared with a natural history control cohort from the Global Alagille Alliance Study (GALA) database. The second late-breaker presentation is a poster which will highlight an analysis of predictors of long-term event-free survival and transplant-free survival in patients with ALGS enrolled in three long-term maralixibat clinical trials.\n\nAll abstracts are now available on the AASLD website and in the October supplement of HEPATOLOGY.\n\nLATE-BREAKER PRESENTATIONS\nOral session\nAbstract LO: Application of real-world evidence analytics: A 6-year event-free survival analysis in Alagille syndrome of the GALA clinical research database and maralixibat treated patients\nBettina E. Hansen, PhD and Binita M. Kamath, MBBChir, on behalf of the GALA study group; presented by Bettina Hansen, Senior Biostatistician, Toronto Centre for Liver Disease, Scientist, Toronto General Hospital Research Institute & Associate Professor, Institute of Health Policy, Management and Evaluation, University of Toronto\nMonday, November 15, 2021 – 12:30 p.m. ET\nThis abstract has been selected as a part of the Best of the Liver Meeting series.\n\nPoster session\nAbstract LP16: Predictors of 6-Year event-free survival in patients with Alagille syndrome treated with maralixibat, an IBAT inhibitor\nRonald J. Sokol, MD, FAASLD, Professor of Pediatrics and Vice Chair of Clinical and Translational Research in the Department of Pediatrics a...